Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,518 total articles
Piper Sandler raised its price target on Byline Bancorp (NYSE:BY) to $37.00 from $35.00 and retained an Overweight rating following stronger-than-expected fourth-quarter results. The firm pointed to net interest margin expansion, higher core fee income and an improving capital position as reasons for boosting earnings estimates and valuation assump…
Scotiabank has reduced its 12-month price target on Datadog to $180 from $217 while retaining a Sector Outperform rating. The bank’s fieldwork points to significant revenue exposure to OpenAI and anticipates stronger top-line growth in 2026 than management guidance. Multiple other brokerages have issued recent positive notes and price targets, refl…
TD Cowen's latest solar industry survey points to a better-than-expected fourth quarter in 2025 for the U.S. residential solar market and an optimistic demand outlook for 2026. The report underscores rising storage attachment rates, a shift toward prepaid lease products after the 25D tax credit elimination, and potential share gains for firms with …
Bernstein SocGen Group raised its price target on United Airlines to $136 from $129 while keeping an Outperform rating, citing stronger top-line momentum and resilient premium revenue streams. The move follows United's fourth-quarter 2025 adjusted diluted EPS beat and guidance for 2026 that sits above consensus; other brokerages have also increased…
TD Cowen increased its price target on Baker Hughes to $64 from $55 while retaining a Buy rating following stronger-than-expected fourth-quarter EBITDA and guidance that matched forecasts. The firm highlighted outperformance versus the Oil Services ETF, solid order trends, and healthy free cash flow as underpinning the move. Multiple peers have als…
Raymond James raised its price target on Solaris Energy Infrastructure (SEI) to $65 from $60 and reiterated an Outperform rating, pointing to the company's shift into power generation and a growing operated gas turbine fleet. The firm emphasized strong recent revenue growth, a partially contracted pro forma fleet and valuation metrics that it views…
Piper Sandler lowered its price target on Roblox Corp. to $125 from $180 while keeping an Overweight rating, citing the need for more conservative estimates beginning in the second half of 2027. The firm projects robust near-term user and bookings growth but has reduced fiscal 2027 and 2028 bookings forecasts. Other broker views on Roblox vary, wit…
Wedbush raised its price target on Zoom Video to $110 from $95 while keeping an Outperform rating, pointing to stronger adoption of AI features, accelerating ARR growth in key products, and historically low customer churn as justification for a higher multiple. Multiple sell-side firms echoed confidence after Zoom’s latest quarterly results.
RBC Capital reiterated its Outperform rating on Valvoline (NYSE: VVV) and maintained a $44.00 price target, citing what it views as conservative fiscal 2026 EBITDA guidance as the company integrates Breeze Autocare. RBC projects modest same-store sales growth for the first quarter of fiscal 2026 and expects adjusted EBITDA slightly above consensus.…
Guggenheim has raised its price target on Erasca Inc. to $12.00 from $5.00 while keeping a Buy rating, citing progress on the company's pan-RAS and pan-KRAS inhibitor programs and recent financing activity. The shares have gained sharply over the past six months and trade near their 52-week high. The firm models a 30% probability-of-success-adjuste…
H.C. Wainwright trimmed its price target on AudioEye to $18 from $22 but retained a Buy recommendation. The revision follows preliminary fourth-quarter 2025 results showing steady revenue and rising annual recurring revenue, while the firm flagged potential slower growth in 2026 that could cap near-term share gains.
Lucid Capital Markets began coverage of Ucore Rare Metals (OTC: UURAF) with a Buy rating and a $12.00 price target, citing the company’s patent-pending RapidSX separation technology and progress toward a commercial processing plant. The stock traded at $6.80 at the time of the initiation, which implies roughly 76% upside to the assigned target. Luc…
H.C. Wainwright increased its price target for NeuroPace Inc to $19.00 from $18.00 while keeping a Buy rating, citing improved preliminary results for the fourth quarter and full-year 2025 and the prospect of regulatory approval for an expanded epilepsy indication. NeuroPace reported $26.6 million in preliminary Q4 revenue and roughly $100 million …
Guggenheim has reaffirmed a Buy rating and a $15.00 price target on Cabaletta Bio (NASDAQ:CABA), highlighting a commercial approach centered on outpatient administration for rese-cel, the use of fully automated manufacturing via Cellares, and a no-preconditioning strategy. The firm points to forthcoming clinical GMP readiness data and multiple clin…
RBC Capital retained its Sector Perform rating and $745 price objective on Regeneron Pharmaceuticals in a research note published Tuesday. The firm emphasized 2026 as a year when emerging competitors could meaningfully affect Regeneron’s core franchises, even as several other analysts updated their outlooks after the company’s Eylea prerelease and …
Needham has kept its Buy rating and $140.00 price target on Agilysys Inc following the company’s third-quarter fiscal 2026 results. The hospitality software provider beat revenue and EBITDA expectations on subscription growth, but shares fell in after-hours trading amid guidance that implies a modest deceleration in subscription growth for the four…
H.C. Wainwright raised its price target on Exelixis to $52 from $49 and retained a Buy rating after updating a DCF-based valuation. The move follows Exelixis's fiscal year 2026 guidance, which lays out revenue and expense ranges including product revenue, COGS, R&D and SG&A, and an effective tax rate estimate.
RBC Capital has reiterated an Outperform rating and a $350 price target on IBM, highlighting confidence in the company’s positioning in hybrid cloud and artificial intelligence despite recent valuation and software execution questions. Investors will be focused on IBM’s January 28 earnings report and software revenue components, including managemen…
JPMorgan has kept a Neutral rating and an $18.00 price target on Sarepta Therapeutics following the company’s release of topline three-year Phase 3 EMBARK results for Elevidys in ambulatory Duchenne muscular dystrophy (DMD) patients. The data report statistically significant and sustained improvements in key motor endpoints versus a pre-specified p…
Canaccord Genuity has reiterated a Buy rating and set a $32.00 price target on Acadia Pharmaceuticals (ACAD), arguing the shares are undervalued when judged on current approved products alone. Trading near $26.86, the stock aligns with consensus Buy recommendations and appears undervalued by InvestingPro Fair Value metrics. Canaccord also highlight…
Evercore ISI has reaffirmed an Outperform rating on UnitedHealth Group with a $400 price target after the insurer reported fourth-quarter results. The company posted adjusted Q4 EPS in line with consensus, delivered a slightly better-than-expected medical loss ratio, but showed weaker-than-expected Optum margins driven by Optum Health. Fiscal 2026 …
JPMorgan raised its price target on Amphenol to $185 from $160 and reiterated an Overweight rating, citing Amphenol’s completion of the acquisition of CCS from CommScope. The deal increases Amphenol’s exposure to optical and IT & Datacom markets, with JPMorgan forecasting the latter to reach $12.7 billion by 2026 and management guidance indicating …
Evercore ISI maintained an In Line rating and a $113.00 price target for UPS after the company's fourth-quarter 2025 results showed earnings and revenue ahead of consensus. The delivery giant reported adjusted EPS of $2.38 and consolidated revenue of $24.479 billion, while issuing full-year 2026 revenue and margin guidance that left some analysts c…
Cantor Fitzgerald has begun coverage of Strategy (NASDAQ:MSTR), assigning an Overweight rating and a $213 price objective. The firm characterized the company as a novel BTC-centric operating vehicle and used a sum-of-the-parts valuation that blends projected sales multiples with an assumed Bitcoin price. Recent corporate actions, including dividend…
Cantor Fitzgerald reiterated an Overweight rating and a $76.00 price target on W.R. Berkley following the insurer's fourth-quarter 2025 results. While Q4 diluted EPS of $1.13 was a hair below the firm's $1.14 estimate, Cantor Fitzgerald described the result as "effectively in-line overall." The company reported stronger-than-expected revenue and re…
